No consistency in endophthalmitis prophylaxis

Article

Methods of attempting to prevent postoperative endophthalmitis vary widely across the United Kingdom, according to a study published in the May 2008 issue of Eye.

Methods of attempting to prevent postoperative endophthalmitis vary widely across the United Kingdom, according to a study published in the May 2008 issue of Eye.

Patel Gordon-Bennett of the department of ophthalmology at Hinchingbrooke Hospital, Cambridgeshire, UK and colleagues conducted a telephone interview survey with 800 staff from ophthalmic training units across the UK between October and November 2005.

The team found that 99.4% of surgeons (n=795) used a preoperative preparation of povidone-iodine on the skin; 69.8% (n=558) instilled povidone-iodine into the conjunctival sac; and 5.9% (n=47) administered antibiotic eyedrops. During surgery, 17.8% (n=142) administered intracameral antibiotics: 66.4% (n=531) administered subconjunctival cefuroxime, 6.0% (n=48) administered routine gentamycin and 4.9% (n=39) administered alternative subconjunctival antibiotics; 16.8% (n=134) administered topical drops as a single dose. Combination steroid/neomycin drops were used by 64.4% of surgeons (n=515) postoperatively; 26.6% (n=213) administered separate drops.

The study revealed wide variation in the preventative measures employed by surgeons. The most frequently deployed methods of endophthalmitis prophylaxis are administrations of subconjunctival and intracameral cefuroxime.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.